Saluda Medical (SLD) Investor update summary

IPO and Capital Raise

• Raised AUD 231 million from new and existing shareholders, commencing ASX trading under ticker SLD.

• Funds will primarily support commercial expansion, especially doubling the U.S. sales force over the next 12 months.

• Strong backing from well-known institutional investors, continuing support post-IPO.

Company Overview and Leadership

• Commercial-stage med tech company focused on neuromodulation for chronic neurological conditions.

• Leadership and board include highly experienced industry figures, such as ex-CEOs from major med tech firms and recent appointments in CEO, CFO, CCO, and COO roles.

• Board members have backgrounds in founding, operating, and investing in medical device and healthcare companies, with experience at firms like Cochlear, Commonwealth Bank, and iRhythm Technologies.

• Founded in Sydney in 2010, with a third of 450 employees based in Australia and all R&D conducted there.

Technology and Innovation

• Developed a closed-loop, neural-sensing and modulation platform, initially applied to spinal cord stimulation (SCS) for chronic pain.

• Technology adapts stimulation in real time, calculates optimal dosing, and measures nerve response, enabling personalized therapy and reducing opioid dependence.

• Technology adjusts stimulation up to 4 million times daily, maintaining optimal pain relief.

• Holds a robust IP portfolio with about 300 patents, creating significant barriers to entry.